The MCh Surgical Oncology and DrNB Surgical Oncology examinations (NBE / Association of Surgeons of India) demand comprehensive oncological reasoning. Practise with thousands of questions across GI, breast, endocrine, HPB, sarcoma and peritoneal malignancy, each referenced to NCCN, ESMO and AJCC 8th Edition and built for both the theory paper and the clinical viva.
Content reviewed 26 August 2026 against current guidelines.
Start practising freeTaken from the bank, not written for this page. Answer it in your head, then open the explanation.
A 72-year-old man with borderline resectable pancreatic cancer is planned for neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy. His preoperative CT scan is analyzed for body composition. At which anatomic landmark is skeletal muscle area routinely measured on CT to assess sarcopenia, and what is the clinical significance of this measurement?
Correct answer: C
✓ Correct answer: CT-based body composition analysis at the L3 vertebral level is the gold standard for assessing sarcopenia in surgical oncology. At L3, a single axial CT slice captures the psoas, paraspinal, transversus abdominis, internal oblique, external oblique, and rectus abdominis muscles. The total skeletal muscle area (cm2) is normalized to height2 to calculate the skeletal muscle index (SMI, cm2/m2). Established cutoffs for sarcopenia (typically SMI <52.4 cm2/m2 for men and <38.5 cm2/m2 for women, per Martin et al.) predict: (1) Increased postoperative complications (Clavien-Dindo grade III-V). (2) Shorter overall survival across multiple cancer types (pancreatic, colorectal, gastric, hepatobiliary). (3) Reduced chemotherapy tolerance and increased dose-limiting toxicity. (4) Longer ICU and hospital stays. This information is available from staging CTs that patients already receive, requiring no additional testing -- only software analysis of existing images. ✗ Why the others are wrong: A: The standard level is L3, not T12. Sarcopenia impacts far more than wound infection -- it is independently associated with overall survival, major complications, chemotherapy tolerance, and ICU stays. It is a systemic prognostic marker, not merely a wound healing predictor. C: L5-S1 is not the standard level for sarcopenia assessment. While psoas dimensions at L5-S1 have been used in some studies, L3 is the validated and internationally accepted standard because it captures a comprehensive cross-section of all major abdominal muscle groups. D: The L3 level is specifically chosen because it has been validated against whole-body MRI/DEXA measurements. Different lumbar levels are NOT equivalent. Sarcopenia assessment is validated across all adult age groups in cancer patients, not limited to those over 80. E: CT-based body composition analysis at L3 measures BOTH skeletal muscle area and adipose tissue compartments (visceral, subcutaneous, intramuscular). CT is actually superior to DEXA for distinguishing muscle from fat in the abdominal compartment and is the accepted standard in surgical oncology research. Teaching point: L3-level CT body composition is the gold standard for sarcopenia assessment in surgical oncology. It uses staging CTs already obtained, requires no additional tests, and provides powerful prognostic information for surgical planning and prehabilitation. Board pearl: Sarcopenia = low skeletal muscle index at L3 on CT. Cutoffs: men <52.4 cm2/m2, women <38.5 cm2/m2 (Martin criteria). Predicts complications, survival, and chemo tolerance. Key concept: it uses EXISTING staging CT scans -- no extra test needed. Pitfall: Sarcopenia and cachexia are not synonymous. Sarcopenia refers specifically to low muscle mass (and can occur in obese patients -- sarcopenic obesity). Cachexia is a multifactorial syndrome of weight loss and muscle wasting. An obese patient can be sarcopenic.
Teaching point. L3-level CT body composition is the gold standard for sarcopenia assessment in surgical oncology. It uses staging CTs already obtained, requires no additional tests, and provides powerful prognostic information for surgical planning and prehabilitation.
Referenced to ESPEN Sarcopenia Guidelines 2023; ERAS Society Prehabilitation
Every question is explained like this — start with 50 free ›Every question is written by Pablo Lozano Lominchar, MD, PhD, and mapped to this board’s published syllabus. Before it enters the bank it has to pass an automated check: five options, a written explanation, and a citation — a named society guideline or a named trial. Benign and functional topics cannot be published without a society guideline; oncological ones cite NCCN, ESMO or AJCC, and the classification systems that govern a topic — Bethesda, TIRADS, Atlanta, Prague, Chicago — have to appear where they apply. The author has audited the full active bank against current guideline versions: what fails is re-cited, rewritten or withdrawn. 650 questions are currently withdrawn and are served to nobody.
Build structured oncological reasoning — staging, surgical principle, operative decision and systemic therapy context — for every tumour site. Master AJCC 8th Edition TNM, practise high-volume timed questions, and rehearse case presentations with MDT rationale for the viva.
SurgBoardsQ&A offers more than 7,300 surgical oncology practice questions covering the full MCh/DrNB syllabus, each with a detailed, guideline-referenced explanation.
Both are 3-year super-specialty routes with a theory-plus-clinical exit exam. MCh (university/NMC) has four theory papers plus a clinical/practical examination with viva; DrNB (NBEMS) has three theory papers (300 marks) plus an OSCE/clinical and viva (300 marks). The DrNB super-specialty exam is held twice a year; MCh timing is set by each university. There is no separate "FNB Surgical Oncology".
Yes — 50 practice questions are free with no credit card required.
Start practising for MCh / DrNB
50 questions free, no credit card required. Filter by board, topic, or difficulty. Explanations cite current ESMO and NCCN guidelines.
Create free account